Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers

50Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Although new agents are implemented to cancer therapy, we lack fundamental understandings of the mechanisms of chemoresistance, the main obstacle to cure in cancer. Here we review clinical evidence linking molecular defects to drug resistance across different tumour forms and discuss contemporary experimental evidence exploring these mechanisms. Although evidence, in general, is sparse and fragmentary, merging knowledge links drug resistance, and also sensitivity, to defects in functional pathways having a key role in cell growth arrest or death and DNA repair. As these pathways may act in concert, there is a need to explore multiple mechanisms in parallel. Taking advantage of massive parallel sequencing and other novel high-throughput technologies and base research on biological hypotheses, we now have the possibility to characterize functional defects related to these key pathways and to design a new generation of studies identifying the mechanisms controlling resistance to different treatment regimens in different tumour forms. © 2013 Macmillan Publishers Limited.

Cite

CITATION STYLE

APA

Lønning, P. E., & Knappskog, S. (2013, November 14). Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers. Oncogene. https://doi.org/10.1038/onc.2013.48

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free